Tesaro Inc. (NASDAQ:TSRO) had its target price boosted by Royal Bank Of Canada from $122.00 to $128.00 in a report published on Monday morning. The brokerage currently has an outperform rating on the biopharmaceutical company’s stock.
Several other analysts also recently issued reports on TSRO. Zacks Investment Research downgraded shares of Tesaro from a hold rating to a sell rating in a research report on Wednesday, June 15th. FBR & Co boosted their price target on shares of Tesaro from $65.00 to $93.00 and gave the stock an outperform rating in a report on Wednesday, June 29th. Jefferies Group downgraded shares of Tesaro from a buy rating to a hold rating and boosted their price target for the stock from $53.00 to $75.00 in a report on Thursday, June 30th. They noted that the move was a valuation call. Leerink Swann boosted their price target on shares of Tesaro from $65.00 to $95.00 and gave the stock an outperform rating in a report on Thursday, June 30th. Finally, Mizuho restated an outperform rating and issued a $67.00 price objective on shares of Tesaro in a research note on Thursday, June 30th. Two investment analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company’s stock. The company has an average rating of Buy and an average price target of $109.76.
Tesaro (NASDAQ:TSRO) traded down 1.75% during mid-day trading on Monday, reaching $115.85. 471,127 shares of the company’s stock traded hands. The company has a 50 day moving average price of $97.07 and a 200-day moving average price of $69.78. Tesaro has a 12 month low of $29.51 and a 12 month high of $122.89. The stock’s market cap is $5.95 billion.
Tesaro (NASDAQ:TSRO) last released its quarterly earnings data on Thursday, August 4th. The biopharmaceutical company reported ($1.28) earnings per share for the quarter, beating the consensus estimate of ($1.71) by $0.43. The company earned $36.60 million during the quarter, compared to analyst estimates of $4.98 million. Tesaro had a negative net margin of 783.97% and a negative return on equity of 205.63%. During the same quarter in the previous year, the business posted ($1.51) EPS. On average, analysts anticipate that Tesaro will post ($7.36) EPS for the current year.
In other news, VP Jeffrey H. Hanke sold 29,166 shares of Tesaro stock in a transaction dated Tuesday, August 30th. The stock was sold at an average price of $86.04, for a total transaction of $2,509,442.64. Following the transaction, the vice president now directly owns 29,166 shares of the company’s stock, valued at approximately $2,509,442.64. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, VP Edward C. English sold 7,000 shares of Tesaro stock in a transaction dated Thursday, September 8th. The shares were sold at an average price of $88.54, for a total value of $619,780.00. Following the transaction, the vice president now directly owns 3,500 shares in the company, valued at $309,890. The disclosure for this sale can be found here. 40.50% of the stock is owned by company insiders.
Hedge funds and other institutional investors have recently bought and sold shares of the stock. BlackRock Fund Advisors increased its stake in shares of Tesaro by 1.8% in the first quarter. BlackRock Fund Advisors now owns 1,293,906 shares of the biopharmaceutical company’s stock valued at $56,971,000 after buying an additional 23,384 shares during the period. BlackRock Inc. increased its stake in Tesaro by 13.3% in the first quarter. BlackRock Inc. now owns 7,096 shares of the biopharmaceutical company’s stock worth $312,000 after buying an additional 834 shares during the last quarter. venBio Select Advisor LLC purchased a new stake in Tesaro during the first quarter worth about $6,605,000. Pictet Asset Management Ltd. increased its stake in Tesaro by 35.8% in the first quarter. Pictet Asset Management Ltd. now owns 55,000 shares of the biopharmaceutical company’s stock worth $2,225,000 after buying an additional 14,500 shares during the last quarter. Finally, Emerald Acquisition Ltd. purchased a new stake in Tesaro during the second quarter worth about $23,685,000. 88.81% of the stock is currently owned by hedge funds and other institutional investors.
TESARO, Inc is an oncology-focused biopharmaceutical company. The Company acquires, in-licenses and develops oncology product candidates. It operates in business of developing and commercializing oncology-focused therapeutics segment. It has in-licensed and are developing oncology-related product candidates, including intravenous (IV) rolapitant and niraparib, as well as product candidates under its immuno-oncology platform.
Receive News & Ratings for Tesaro Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tesaro Inc. and related companies with MarketBeat.com's FREE daily email newsletter.